NCT01789320View on ClinicalTrials.gov

Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
UveitisIntermediate UveitisPosterior UveitisPanuveitisNoninfectious Uveitis
Interventions
DRUG

triamcinolone acetonide (Triesence®)

4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space

Trial Locations (3)

44195

Cleveland Clinic Foundation, Cleveland

60611

Northwestern University, Chicago

68198

University of Nebraska Medical Center, Omaha

Sponsors
All Listed Sponsors
lead

Clearside Biomedical, Inc.

INDUSTRY